'NASDAQ Biotech' Promises to Erase Cancer, Market Cap Soars by 700 Billion in One Day

Nasdaq‐listed cancer drug developer Erasca (ERASCA INC: ERAS) jumped 8.13% to close at $17.95. Its market capitalization rose to about $5.58 billion (roughly KRW 7.5 trillion), gaining around $490 million (approximately KRW 670 billion) in a single day. Trading volume surged to 3.92 million shares, reflecting strong demand.

In January, the company announced positive early clinical data for its core pipeline candidate ERAS-0015, showing partial responses across multiple tumor types, and outlined development milestones for 2026–2027. In March, Erasca revealed a clinical collaboration to evaluate a combination therapy of ERAS-0015 with Tango Therapeutics’ vopimetostat. Previously in February, it secured about $240 million through a public offering, extending its cash runway into the first half of 2029.

Erasca is a clinical-stage biotech focused on precision oncology therapies targeting cancers driven by the RAS/MAPK signaling pathway, with the ambitious goal of “erasing cancer.” Its lead assets are the pan-RAS molecular glue ERAS-0015 and the pan-KRAS inhibitor ERAS-4001, positioning the company as a later entrant in the highly competitive RAS-targeted oncology market.